Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation

YEGİN Z. A., ÖZKURT Z. N., Aki S. Z., Sucak G. T.

TRANSFUSION AND APHERESIS SCIENCE, vol.42, no.3, pp.239-245, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 42 Issue: 3
  • Publication Date: 2010
  • Doi Number: 10.1016/j.transci.2010.03.011
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.239-245
  • Keywords: Acute leukemia, Donor lymphocyte infusion, Hematopoietic stem cell transplantation, VERSUS-HOST-DISEASE, LEUKOCYTE INFUSIONS, OUTCOMES, THERAPY, TRIAL
  • Gazi University Affiliated: Yes


Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell transplantation (HSCT). In this retrospective study, 23 patients 115 (65.2%) AML, 8 (34.8%) ALL] who received DLI +/- reinduction chemotherapy for post-transplant relapse were reviewed. The overall response rate of DLI was 66.7% for AML and 50% for ALL A total of 15 patients (65.2%) developed acute graft versus host disease (GVHD). Response rates were higher in patients with GVHD (80% versus 25%; p = 0.01; OR: 12.0). The probability of OS was better in patients who respond to DLI (p = 0.04). Further strategies are required to improve the anti-tumor properties of alloreactive donor lymphocytes and to obtain durable responses with DLI in patients with relapsed acute leukemia after allogeneic HSCT. (C) 2010 Elsevier Ltd. All rights reserved.